WAY-100635 for 5-HT1A Pain Circuit Assays

2026-08-24

WAY-100635 provides a precise pharmacological test for whether 5-HT1A signaling contributes to pain, affect, and circuit-level responses. Its combination of high affinity, silent antagonism, and compatibility with binding, functional, behavioral, and imaging workflows makes it a practical complement to cannabidiol studies.

Metabolism of Sumatriptan: CYP and MAO Revisited

2026-08-24

The reference study revises the prevailing view that sumatriptan is metabolized mainly through monoamine oxidase A by demonstrating additional cytochrome P450-mediated N-demethylation. Its recombinant-enzyme and HPLC–MS design provides a clearer framework for interpreting metabolite formation, drug-interaction hypotheses, and translational serotonergic signaling research.

Sumatriptan’s Anti-Inflammatory Evidence Beyond Migraine

2026-08-23

This systematic review reframes sumatriptan as more than an acute migraine therapy by synthesizing evidence for cytokine, NF-κB, nitric oxide, CGRP, and cell-survival effects across inflammatory models. Its findings support further mechanistic and translational research while emphasizing that the current evidence remains heterogeneous and predominantly preclinical.

ML365: TASK1 Workflows and Research Applications

2026-08-22

ML365 combines nanomolar TASK1 inhibition with assay flexibility for ion-channel, neuroinflammation, and target-validation studies. This guide translates channel engagement into practical workflows while addressing mGluR5 activity, platform-dependent potency, and experimental confounders.

From Fluorescent mRNA Tracking to Translational Insight

2026-08-22

A thought-leadership framework for using ARCA Cy5 EGFP mRNA (5-moUTP) to connect mRNA delivery, intracellular localization, translation, and immune-response measurements with translational studies such as targeted nanoparticle therapy after ischemic stroke.

BMS-777607 at the MET–Platelet Interface

2026-08-21

BMS-777607 offers a useful case study in how selective kinase pharmacology can connect cancer biology with emerging hiPSC-derived platelet workflows. This thought-leadership article separates validated MET-family inhibition from hypothesis-generating applications, explains how to design translational experiments, and shows why target engagement, model choice, and compound handling matter more than a nominal pathway label.

hiPSC Intestinal Organoids for Pharmacokinetics

2026-08-20

Gastrin I (human) in Organoid Assay Workflows

2026-08-20

Gastrin I (human) provides a defined CCK2 receptor stimulus for dissecting acid-related signaling, parietal-cell responses, and model-dependent gastrointestinal physiology. This guide combines practical peptide handling with a cautious extension of human pluripotent stem cell-derived intestinal organoid methods into comparative assay design.

EdU Imaging Kits (488) for S-Phase Analysis

2026-08-19

EdU Imaging Kits (488) provide a morphology-preserving route to quantify DNA synthesis in imaging and flow cytometry workflows. This practical guide applies the assay to NSCLC cell-cycle studies, with protocol starting points, controls, comparative advantages over BrdU, and troubleshooting strategies.

Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding

2026-08-19

Oliveira and colleagues found that naturally occurring angiotensin fragments can enhance SARS-CoV-2 spike-protein binding to host receptors, with the strongest effects observed for selected shorter peptides and the spike–AXL interaction. The study provides a structure–activity framework linking peptide truncation and Tyr4 modification to receptor-binding changes, while also showing why cellular and physiological validation is still required.

CP-673451: Selective PDGFRα/β Assay Guide

2026-08-18

CP-673451 gives cancer researchers a focused way to interrogate PDGFRα/β signaling across phosphorylation, viability, angiogenesis, and xenograft workflows. Its nanomolar cellular activity and biomarker-oriented use in glioma models make it especially useful for connecting pathway inhibition with ATRX-defined response patterns.

Cediranib (AZD2171) for VEGFR Assays

2026-08-18

Cediranib (AZD2171) is a potent angiogenesis inhibitor for separating VEGFR pathway signaling from changes in proliferation and cell death. This workflow combines phospho-Akt measurements, concentration–response testing, and paired viability endpoints to improve interpretation in cancer research.

Nebivolol hydrochloride Assay Guide

2026-08-17

A scenario-driven guide to using Nebivolol hydrochloride (SKU B1341) in cell viability, proliferation, and cytotoxicity workflows. It covers receptor-specific interpretation, DMSO compatibility, assay controls, mTOR-screening boundaries, and practical product-selection criteria.

Drug-Sensitized Yeast for mTOR Inhibitor Discovery

2026-08-17

Breen and colleagues developed a genetically drug-sensitized Saccharomyces cerevisiae platform that markedly improves detection of TOR/mTOR pathway inhibitors. The system distinguishes TOR1-dependent growth inhibition at substantially lower concentrations than wild-type yeast and provides a practical early-stage screen for geroscience and oncology programs.

Methylprednisolone Sodium Succinate Lab Workflows

2026-08-16

Build more informative inflammation, leukocyte, and tumor-cell assays with a water-compatible synthetic corticosteroid and concentration-aware controls. This guide turns Methylprednisolone Sodium Succinate into a reproducible workflow for cytokine profiling, ROS testing, chemotaxis, apoptosis, and translational injury-model research.